inno.N

OMAPPLUSONE Inj. and OMAPPLUSONE PERI Inj., Total Parenteral Nutritionare(TPN), are launched

K-CAB 25mg is launched in Korea
K-CAB selects excellent technology in the field of life science for '2023 Industrial Technology Performance'(National Academy of Engineering of Korea)y
K-CAB won the '2023 Industrial Research(IR) 52 Jang Yeong-sil Award'

K-CAB released as a ODT(Orally Disintegrated Tablet) form
K-CAB launches in China ('Taixinzan')
K-CAB enters phase 3 clinical trials in US

Technologies applied to manufacturing K-CAB are exported to U.S.A. and Canada

“K-CAB” received USFDA approval for Phase 1 clinical trials.

K-CAB, the 30th novel drug to be developed and registered in Korea, is launched in tablet form.

K-CAB (with Tegoprazan as the active ingredient) receive approval from the Korean Ministry of Food & Drug Safety to be used as a drug for GERD.
Korea’s 30th novel drug

Technologies for CJ-40001 (second generation EPO) are exported to the China-based company, NCPC Genetech Biotechnology.

Technologies for CJ-40001 (second generation EPO) are exported to the Japan-based company, YL Biologics.

Machkhan, an improved and modified drug for hypertension, is launched
A drug with the combined active ingredients of ARB(angiotensin II receptor blocker) and CCB(calcium-channel blocker)
The first drug to combine the active ingredients of Candesartan /Amlodipine

K-CAB, a novel drug developed in-house to treat GERD is approved by the Korean Ministry of Food and Drug Safety
A novel drug in the category of P-CAB drugs (potassium competitive acid blockers).
Related technologies are exported to Luoxin, China (2015)
Application is filed for approval as a novel drug (2017)

Vogmet, an improved and modified drug to treat diabetes, is launched.
A drug with the combined active ingredients of α-glucosidase and biguanides
The first drug to combine the active ingredients of voglibose and metformin.

Tegoprazan,
Selected by the government as a key initiative for the development of novel drugs in all phases

Exone, a combined drug treatment for hypertension, is launched.
A drug with the combined active ingredients of ARB(angiotensin II receptor blocker) and CCB(calcium-channel blocker)
A drug with the combined active ingredients of Valsartan and
Outstanding photo-stability due to differentiated technologies

inno.N is selected by the Ministry of Health and Welfare as an ‘innovative pharmaceutical firm’.
inno.N is recognized for its outstanding R&D for novel drugs and export capabilities.

Epokine, a treatment for anemia, is launched.
inno.N becomes the first company in Korea and the third company in the world to develop an EPO drug.

Citopcin injection acquires certification for ‘domestic new technologies’ and is given the Chang Young Sil Award.
The first drug in Korea to use TOF, a biological substance

Anti-hangover beverage Condition is launched.
Condition becomes the first anti-hangover beverage to be introduced in the Korean market

Hepaccine-B, a vaccine for Hepatitis B, is launched.
Hepaccine-B is the first vaccine for Hepatitis B to be developed in Korea and the second to be developed in the world.
Certification from the WHO (1993)